Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of “Hold” from Brokerages

Certara, Inc. (NASDAQ:CERT) has been assigned an average recommendation of “Hold” from the thirteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $8.95.

A number of research firms have weighed in on CERT. Stephens dropped their target price on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Craig Hallum dropped their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th. BMO Capital Markets reduced their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Morgan Stanley dropped their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, KeyCorp cut their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th.

Certara Stock Performance

Shares of CERT opened at $8.01 on Thursday. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -17.80 and a beta of 1.44. The business’s fifty day simple moving average is $6.47 and its two-hundred day simple moving average is $6.55. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a current ratio of 2.55, a quick ratio of 1.88 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $93.27 million during the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.Certara’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period last year, the firm posted $0.07 EPS. Research analysts anticipate that Certara will post 0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. increased its position in Certara by 2,733.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after buying an additional 2,870 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of Certara by 28.1% during the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock valued at $75,000 after buying an additional 2,871 shares in the last quarter. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Certara during the 1st quarter valued at approximately $78,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.